Drug intelligence / Profile preview

CanChew+

Development stage: Unknown
Lead developer: Axim Biotechnologies
Modality: Small Molecules
Administration: Oral

Overview

CanChew+ is a controlled-release chewing gum formulation of cannabidiol (CBD) developed by AXIM Biotechnologies. It utilizes a patented microencapsulation technology designed to deliver CBD through the oral mucosal lining, bypassing first-pass metabolism and achieving high bioavailability (approximately 80% within 30 minutes). The product was primarily developed for the treatment of irritable bowel syndrome (IBS) and has been investigated for various other conditions including psychotic disorders, chronic pain, and multiple sclerosis symptoms. Each piece typically contains 10 mg of CBD derived from industrial hemp oil.

Brand names: CanChew+CanChew Plus
Other names: CanChew Plus

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on CanChew+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CanChew+.

Explore the full profile